Protein expression trends of DNMT1 in gastrointestinal diseases: From benign to precancerous lesions to cancer

Table 1 Expression of DNMT1 in different gastric diseases

Group	Cases	(+)		(++)		(+++)		P value
		Cases	Ratio (%)	Cases	Ratio (%)	Cases	Ratio (%)
CSG	90	90	100.00	0	0.00	0	0.00	0.00a
AG/GIM	72	40	55.56	32	44.44	0	0.00	0.044b,0.00c
GLIN	54	21	38.89	31	57.41	2	3.70	0.00d
GHIN	66	1	1.52	53	80.30	12	18.18	0.00e
EGC	71	1	1.41	31	43.66	39	54.93

^aP: CSG vs other groups;

^bP: AG/GIM vs GLIN;

^cP: AG/GIM vs GHIN and EGC;

^dP: GLIN vs GHIN and EGC;

^eP: GHIN vs EGC. CSG: Chronic superficial gastritis; AG/GIM: Atrophic gastritis with intestinal metaplasia; GLIN: Gastric low-grade intraepithelial neoplasia; GHIN: Gastric high-grade intraepithelial neoplasia; EGC: Early gastric cancer.

Table 2 Expression DNMT1 in different intestinal diseases

Group	Cases	(+)		(++)		(+++)		P value
		Cases	Ratio (%)	Cases	Ratio (%)	Cases	Ratio (%)
NIM	90	82	91.11	8	8.89	0	0.00	0.00a
ILIN	54	25	46.30	29	53.70	0	0.00	0.00b
IHIN	71	9	12.68	51	71.83	11	15.49	0.00c
ECRC	82	4	4.88	28	34.15	50	60.98

^aP: NIM vs other groups;

^bP: ILIN vs other groups;

^cP: IHIN vs ECRC. NIM: Normal intestinal mucosa; ILIN: Intestinal low-grade intraepithelial neoplasia; IHIN: Intestinal high-grade intraepithelial neoplasia; ECRC: Early colorectal cancer.